Blog › FDA approved small molecules

Synthesis of Iberdomide (ZENBEXUS) — Drug Intelligence Dossier

astinovabiolabs · · 5 min read

Mechanism: Iberdomide is a potent, orally available cereblon (CRBN) E3 ligase modulator (CELMoD). It binds CRBN — the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase — and reshapes the substrate-recruitment surface to drive ubiquitination and proteasomal degradation of the myeloma-survival transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). Relative to the first-generation IMiDs lenalidomide and pomalidomide, iberdomide binds CRBN with ~20-fold higher affinity (reported CRBN-binding IC50 ~150 nM), giving deeper/more complete Ikaros-Aiolos degradation and retained activity in lenalidomide/pomalidomide-resistant myeloma cells with dysregulated CRBN. Downstream effects are dual: direct anti-myeloma (apoptosis, suppression of the IRF4/MYC axis) plus immunomodulatory T-cell and NK-cell co-stimulation, with preclinical synergy alongside dexamethasone, proteasome inhibitors and anti-CD38 antibodies. The CRBN-DDB1-CC-220 co-crystal structure (Matyskiela et al., 2018) shows the morpholinomethyl-benzyloxy arm making additional cereblon contacts away from the Ikaros/Aiolos interface, rationalising the affinity gain. Refs: PMID 28425720 (crystal/medchem), PMID 29945920 (Ikaros/Aiolos PD).

t½: Terminal t½ ~9-13 h (single dose) — supports once-daily dosing on the 21-of-28-day schedule · Tmax: Oral; absorbed with a Tmax of a few hours [VERIFY vs label §12.3]

Synthesis Route of the Originator

Disclosed kilogram-scale process (Zacuto et al., Org. Process Res. Dev. 2024, 28(1), 46-56 and 57-66) reconstructed at the level of disclosed building blocks and step order. Three fragments converge from the L-glutamine chiral pool. Methyl 3-hydroxybenzoate is Duff-formylated ortho to the phenol to the salicylaldehyde ester (INT-A1); Williamson O-alkylation with 4-(morpholinomethyl)benzyl chloride (from selective mono-alkylation of 1,4-bis(chloromethyl)benzene with morpholine) installs the benzyl ether (INT-A2). Reductive amination of the aldehyde with L-glutamine tert-butyl ester followed by intramolecular lactamisation builds the 1-oxoisoindoline (INT-A3), carrying the open glutaramide. Finally, tert-butyl ester cleavage and glutarimide (imide) ring closure — deliberately the LAST step, run under controlled conditions to protect the labile (S) C3 centre — give iberdomide, isolated as the hydrochloride. STEREO: the single (S) stereocentre traces from L-glutamine (2S) with retention throughout; 

aReagents and conditions: (1) Hexamethylenetetramine (HMTA), acid (AcOH/TFA), heat — regioselective ortho-formylation between the phenol and the ester to give the salicylaldehyde ester.; (2) 4-(morpholinomethyl)benzyl chloride (BB3, 1.0-1.1 eq; from mono-alkylation of 1,4-bis(chloromethyl)benzene [CAS 623-25-6] with morpholine [CAS 110-91-8]), K2CO3, DMF or MeCN, 50-80 °C. Controlled stoichiometry on BB3 formation avoids the bis-morpholino impurity.; (3) L-glutamine tert-butyl ester (BB1, H-Gln-OtBu; CAS 39741-62-3 as HCl salt), NaBH(OAc)3 or NaBH4 (chemoselective imine reduction sparing the aryl ester), then intramolecular lactamisation (benzylamine onto the aryl ester → 1-oxoisoindoline). Sets/retains (S) from the L-glutamine chiral pool.; (4) Acid (TFA or HCl) removes the tert-butyl ester; the liberated alpha-acid cyclises onto the gamma-primary amide to close the piperidine-2,6-dione (glutarimide) under CDI or thermal/coupling conditions. Run LAST and under controlled conditions (OPRD Part 2) to preserve the labile (S) C3 stereocentre. Free base C25H27N3O5, MW 449.51.; (5) The marketed ZENBEXUS drug substance is iberdomide hydrochloride (C25H27N3O5·HCl; per FDA label DESCRIPTION). Treat the free base with HCl in a suitable solvent and crystallise. (The OPRD process papers developed the besylate/BSA salt as an isolation/process form; the registered form is the HCl.).

Key intermediates

Crystal Forms, Salts, and Solid-State Profile

  • API in approved drug product: Iberdomide hydrochloride (C25H27N3O5·HCl; MW ~485.97 salt / 449.51 free base) is the marketed ZENBEXUS drug substance (per FDA label DESCRIPTION). Chemical name: (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione hydrochloride. (The BMS/Celgene OPRD process papers developed the besylate/BSA salt as an isolation form; the registered form is the HCl.)
  • Strengths approved: EQ 1 mg and EQ 0.75 mg base oral capsules; 1 mg QD Days 1-21 of 28-day cycles.
  • Third-party polymorph activity: No third-party US solid-form activity confirmed as of curation [VERIFY SureChEMBL/Espacenet].
  • Originator polymorph filing: Celgene/BMS HCl-salt crystalline-form patent expected (secondary estate) [VERIFY exact number once Orange Book lists Zenbexus].

Available experimental protein structures (RCSB PDB)

PDB IDTargetTitleResolution (Å)MethodReleased
1R6JInterleukin-1 betaUltrahigh resolution Crystal Structure of syntenin PDZ20.73X-RAY DIFFRACTION2004-05-04
32OAInterleukin-1 betaThe ultra-high-resolution hyaluronan-binding…0.775X-RAY DIFFRACTION2026-08-12
7R2HInterleukin-1 beta0.79A resolution structure of DMSO bound Cyclophilin D0.79X-RAY DIFFRACTION2023-02-15
9V09Protein cereblon/Zinc finger…Cryo-EM structure of lenalidomide-organized…3.25ELECTRON MICROSCOPY2026-08-19
9V0CProtein cereblon/Zinc finger…Cryo-EM structure of iberdomide-organized…3.27ELECTRON MICROSCOPY2026-08-19
9UUMProtein cereblon/Zinc finger…Cryo-EM structure of mezigdomide-organized…3.41ELECTRON MICROSCOPY2026-06-10
2FMATumor necrosis factorStructure of the Alzheimer’s Amyloid Precursor…0.85X-RAY DIFFRACTION2007-01-16
6ZSYTumor necrosis factorCrystal structure of the Grindelwald…0.926X-RAY DIFFRACTION2021-03-31
4XDXTumor necrosis factorThe crystal structure of soluble human…0.95X-RAY DIFFRACTION2015-12-23

For SAR / docking and ligand-bound forms relevant to polymorph analysis.

Clinical & Regulatory Profile

5.1 Approved indication

  • Approval date (US): 2026-08-13
  • NDA number: NDA 221075
  • Brand (US): ZENBEXUS
  • Indication: In combination with daratumumab and hyaluronidase-fihj and dexamethasone (regimen ‘ZDd’), for adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor AND an immunomodulatory agent. FIRST-IN-CLASS: the first cereblon E3 ligase modulator (CELMoD) approved for multiple myeloma. Approved under ACCELERATED APPROVAL based on MRD-negative complete response (CR) at any time; continued approval may be contingent on verification of clinical benefit in the confirmatory portion of EXCALIBER-RRMM.

Key peer-reviewed literature